注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Auris Medical Holding AG是一家瑞士的生物技术公司,专注于神经病学、鼻科、过敏和中枢神经系统(CNS)疾病的治疗和医疗设备的开发和商业化。该公司活跃于三个领域,如:开发用于肝外治疗靶点的寡核苷酸-OligoPhore平台;预防空气传播病毒和过敏原的鼻喷剂Bentrio或治疗眩晕的AM-125;开发治疗耳鸣的Keyzilen或听力损失的Sonsuvi的鼓室内治疗方法。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
David Baguley | - | 2019 | Member of Tinnitus's Scientific Advisory Board |
Hinrich Staecker | - | 2019 | Member of Tinnitus's Scientific Advisory Board |
Wolfgang Arnold | 81 | 2007 | Member of Tinnitus's Scientific Advisory Board |
Alain H. Munoz | 74 | 2018 | Independent Non-Executive Director |
Mats Peter Blom | 58 | 2017 | Independent Non-Executive Director |
Margrit Schwarz | 59 | 2021 | Independent Director |
Richard Salvi | - | 2019 | Member of Tinnitus's Scientific Advisory Board |
Thomas Meyer | 56 | 2003 | Founder, President, Chairman, CEO & MD |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核